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Abstract
The appropriate therapy for metastatic breast cancer must be selected based on the immunohistochemical
phenotype of the cancer. However, biopsy for metastatic lesions is difficult. We herein report a patient with
incidental appendicitis caused by a metastatic breast cancer which was successfully treated with effective
therapy chosen based on the pathological diagnosis obtained on resection. The patient was a 56-year-old
female with right breast cancer and an immunohistochemical status of estrogen receptor (ER) (+),
progesterone receptor (PgR) (+), human epidermal growth factor receptor 2 (HER2) (3+), and Ki67 40 %.
She received epirubicin and cyclophosphamide therapy followed by docetaxel and trastuzumab, and total
mastectomy with axillary dissection was performed. Thereafter, she received postmastectomy radiation,
adjuvant trastuzumab, and adjuvant hormone therapy with letrozole. One year and 8 months after the
operation, she developed right hydronephrosis and swollen para-aortic lymph nodes and her hormone
therapy was changed to fulvestrant therapy. However, she additionally developed left hydronephrosis and
multiple bone metastases, and pertuzumab, trastuzumab, and docetaxel therapy was started. After six cycles,
her disease became well-controlled, and maintenance with pertuzumab and trastuzumab was introduced.
However, after another 7 months, she developed new vertebral metastasis and acute appendicitis and
laparoscopic appendectomy was performed. A pathological investigation of the resected appendix revealed
some clusters of atypical cells in the subserosa and muscle layer, which showed an immunohistochemical
status of ER (+), PgR (−), HER2 (3+), and E-cadherin (−). These findings led to the diagnosis as appendiceal
metastasis of invasive lobular carcinoma (ILC) from the breast. Thereafter, she received trastuzumab-DM1
and her disease was well-controlled again. Appendicitis caused by breast cancer is very rare. However, ILC
sometimes develops metastases in the abdominal cavity; an appendiceal tumor should therefore be
included in the differential diagnosis. A pathological diagnosis of metastatic tumor could be very useful for
selecting the effective therapy.
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Background
The appropriate therapy for metastatic breast cancer
must be selected based on the immunohistochemical
phenotype of the cancer, such as the estrogen receptor
(ER) status and human epidermal growth factor 2
(HER2) status. Hormone therapy is indicated for ER-
positive cases, and anti-HER2 therapy is restricted to
HER2-positive cases. However, in many cases, therapy
for metastatic breast cancer is determined based on
the immunohistochemical phenotype of the primary
site resected in a radical operation, as biopsy for
metastatic lesions is difficult. If the selected therapy
has no effect, another therapy must be tried, or a
pathological diagnosis for the metastatic lesion must be
obtained via a difficult technique, such as computed
tomography (CT)-guided biopsy, bone biopsy, or laparo-
tomic biopsy, since the immunohistochemical phenotype
can occasionally differ between the primary and metastatic
lesions [1].
We herein report a patient with incidental appendicitis
caused by a metastatic breast cancer which was success-
fully treated with effective therapy chosen based on the
pathological diagnosis obtained on resection.
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Case presentation
The patient was a 56-year-old female with no remarkable
medical history. She visited our hospital with a chief
complaint of a right breast mass in April 2011. The mass in
the upper medial portion of her right breast was a 3-cm-
diameter tumor with an unclear border on mammography,
ultrasonography (US), and magnetic resonance imaging
(MRI) (Fig. 1a), and the lymph nodes in the axilla and
subclavian were swollen (Fig. 1b). The results of a histo-
logical examination for a core needle biopsy specimen were
a breast cancer (invasive ductal carcinoma) with an immu-
nohistochemical status of ER (+), progesterone receptor
(PgR) (+), HER2 (3+), and Ki67 40 %. She received four
cycles of epirubicin and cyclophosphamide therapy
followed by four cycles of docetaxel and trastuzumab as
preoperative chemotherapy, and total mastectomy with
axillary dissection was performed in December 2011
(Fig. 1c). A postoperative pathological investigation revealed
that almost all of the tumor cells on the resected breast and
lymph nodes had disappeared. Thereafter, she received
postmastectomy radiation therapy for the chest wall and
supraclavicular region, adjuvant trastuzumab for 1 year, and
adjuvant hormone therapy with letrozole.
One year and 8 months after the operation, she
developed right hydronephrosis and swollen para-
aortic lymph nodes (Fig. 1d) and her hormone therapy
was changed to fulvestrant therapy. However, she
additionally developed left hydronephrosis and mul-
tiple bone metastases in the skull, right acetabulum,
and right iliac crest 5 months after the therapy was
changed (Fig. 1e). Pertuzumab, trastuzumab, and doce-
taxel therapy was started after left nephrostomy, and
after six cycles of the therapy, the bone metastases had
shrunk (Fig. 1f ) and her bilateral hydronephrosis was
relieved. Her disease seemed to be well-controlled.
Therefore, maintenance therapy with pertuzumab and
trastuzumab (without docetaxel) was introduced and
the nephrostomy tube was removed.
Seven months after the start of maintenance therapy,
she developed new vertebral metastasis (Fig. 2a) and
visited the emergency ward at our hospital complaining
of right lower abdominal pain. Computed tomography
Fig. 1 The images and surgical specimens obtained before the patient developed acute appendicitis. a Breast tumor on mammography, US, and
MRI at the first visit. b Axillary lymph nodes on MRI at the first visit. c The surgical specimen obtained at mastectomy. d Right hydronephrosis and
swollen para-aortic lymph nodes on CT and PET. e Left hydronephrosis and bone metastases on CT, PET, and MRI. f Right femoral bone metastasis
after the start of pertuzumab, trastuzumab, and docetaxel therapy on MRI
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showed a swollen appendix with fecal stones (Fig. 2b),
and a blood test revealed elevated white blood cells
(16,270/μl) and CRP (7.07 mg/dl), suggesting acute
appendicitis (Fig. 2b). Laparoscopic appendectomy was
performed (Fig. 2c). The pathological findings showed
infiltration of neutrophils within the submucosa and
subserosa, which were consistent with gangrenous
appendicitis. Further investigation of the specimen
revealed some clusters of atypical cells in the subserosa
and muscle layer (Fig. 2d).
An immunohistochemical analysis of the breast tumor
showed ER (+), PgR (+), HER2 (3+), and E-cadherin (−)
(Fig. 3a), while that of the appendiceal tumor showed ER
(+), PgR (−), HER2 (3+), and E-cadherin (−) (Fig. 3b).
Although the expression of PgR differed between the
breast tumor and appendiceal tumor, both tumors had
similar morphologic features, overexpression of HER2,
and loss of E-cadherin, and we therefore concluded that
the appendiceal tumor was a metastasis from invasive
lobular carcinoma (ILC) of the breast.
Thereafter, she received trastuzumab-DM1 therapy,
since the appendiceal tumor still had overexpression of
HER2, after which the metastatic tumors detected on
PET/CT almost disappeared again (Fig. 2e).
Discussion
We experienced having a patient with appendicitis
caused by a metastasis of ILC. Thanks to the immuno-
histochemical analysis of the resected appendiceal
tumor, we succeeded in continuing effective anti-
HER2 therapy.
ILC of the breast accounts for 14 % of all breast cancer
cases [2] and presents with a loss of E-cadherin expression
[3]. It can metastasize to the abdominal cavity as peritoneal
dissemination, para-aortic lymph node swelling, and small
bowel metastasis. Arpino et al. reported that ILC and
invasive ductal carcinoma (IDC) develop such metastases
in 6.7 and 1.8 % of cases, respectively [4]. In our case, we
failed to obtain the histological diagnosis of ILC at the
initial therapy session. However, the metastatic pattern of
Fig. 2 The images at the time of development and after the patient developed acute appendicitis. a New vertebral metastasis on PET and MRI.
b Swollen appendix on axial and coronal CT. c An image taken during laparoscopic appendectomy. d A specimen obtained at appendectomy.
e PET images after the start of trastuzumab-DM1
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her disease, such as para-aortic lymph node swelling and
hydronephrosis, made us suspect ILC, and we succeeded in
detecting carcinoma cells that were E-cadherin (−) in the
resected appendix.
Connor et al. reported that incidental appendiceal
tumor detected after appendectomy accounts for only
0.9 % of cases (74/7990), and among them, metastatic
tumor was only found in 11 cases [5]. Yoon et al. pre-
viously reported 139 cases with metastatic appendiceal
tumors, with primary sites mainly consisting of ovary
(56 cases), colon (35 cases), and stomach (7 cases). No
cases of appendiceal metastasis from breast cancer
were described in their study [6], indicating that
appendicitis caused by the metastasis of breast cancer
is very rare.
HER2 expression can sometimes differ between the
primary and metastatic tumors. Amir et al. reported that an
HER2-positive primary tumor and HER2-negative meta-
static tumor account for 12.5 % of cases, while an HER2-
negative primary tumor and HER2-positive metastatic
tumor account for 4.6 % of cases [1]. We must therefore
perform biopsy of the metastatic tumor if anti-HER2
therapy for metastatic breast cancer is less effective than
expected. In the present case, her metastatic tumor seemed
to show resistance to pertuzumab and trastuzumab therapy,
and we could not have selected an appropriate subsequent
therapy without an immunohistochemical analysis of the
resected appendix.
Basic research investigating the efficacy of trastuzumab-
DM1 for HER2-positive breast cancer cell lines has found
that trastuzumab-resistant cells retain sensitivity to
trastuzumab-DM1 [7]. Furthermore, the efficacy of
trastuzumab-DM1 was found to be related to the strength
of HER2 expression, and trastuzumab-DM1 was not
effective against HER2-negative cells [8]. These results
suggest that trastuzumab-DM1 is worth trying even in
cases with trastuzumab-resistant tumors, and biopsy for
metastatic tumors is useful for confirming the strength of
HER2 expression.
Conclusions
Appendicitis caused by breast cancer is very rare. However,
ILC sometimes develops metastases in the abdominal
cavity, and we therefore should suspect an appendiceal
tumor, as in the present patient. A pathological diagnosis of
metastatic tumor could be very useful for selecting the
most effective subsequent therapy.
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Fig. 3 The histopathological and immunohistochemical diagnoses of the breast tumor and appendiceal tumor. a The breast tumor
findings (HE, ER, PR, HER2, E-cadherin). b The appendiceal tumor findings (HE, ER, PR, HER2, E-cadherin)
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